Skip to content
10-Q

Quarterly Report

AVANIR PHARMACEUTICALS, INC.

0001193125-14-298755

← back to feed
Filed
Aug 7, 2014 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2014 · Jul 31, 2014 171.83M sh
Capex Q3 2014 · Jun 30, 2014 $2.47M
Capex Q3 2014 · Jun 30, 2013 $319.61K
Cash And Equivalents Q3 2014 · Jun 30, 2014 $84.97M
Cash And Equivalents Q3 2014 · Sep 30, 2013 $55.26M
Cash And Equivalents Q3 2014 · Jun 30, 2013 $55.02M
Cash And Equivalents Q3 2014 · Sep 30, 2012 $69.78M
Stockholders Equity Q3 2014 · Jun 30, 2014 $66.72M
Stockholders Equity Q3 2014 · Sep 30, 2013 $18.47M
Current Liabilities Q3 2014 · Jun 30, 2014 $36.85M
Current Liabilities Q3 2014 · Sep 30, 2013 $34.79M
Total Liabilities Q3 2014 · Jun 30, 2014 $51.73M
Total Liabilities Q3 2014 · Sep 30, 2013 $57.61M
Current Assets Q3 2014 · Jun 30, 2014 $112.59M
Current Assets Q3 2014 · Sep 30, 2013 $71.84M
Total Assets Q3 2014 · Jun 30, 2014 $118.45M
Total Assets Q3 2014 · Sep 30, 2013 $76.08M
Rd Expense Q3 2014 · Jun 30, 2014 $12.3M
Rd Expense Q3 2014 · Jun 30, 2014 $31.72M
Rd Expense Q3 2014 · Jun 30, 2013 $6.05M
Rd Expense Q3 2014 · Jun 30, 2013 $21.58M
Net Income Q3 2014 · Jun 30, 2014 −$12.7M
Net Income Q3 2014 · Jun 30, 2014 −$36.32M
Net Income Q3 2014 · Jun 30, 2013 −$11.42M
Net Income Q3 2014 · Jun 30, 2013 −$40.03M
Operating Income Q3 2014 · Jun 30, 2014 −$11.89M
Operating Income Q3 2014 · Jun 30, 2014 −$33.66M
Operating Income Q3 2014 · Jun 30, 2013 −$10.41M
Operating Income Q3 2014 · Jun 30, 2013 −$36.93M
Cost Of Revenue Q3 2014 · Jun 30, 2014 $1.49M
Cost Of Revenue Q3 2014 · Jun 30, 2014 $4.15M
Cost Of Revenue Q3 2014 · Jun 30, 2013 $1.08M
Cost Of Revenue Q3 2014 · Jun 30, 2013 $2.85M
Revenue Q3 2014 · Jun 30, 2014 $28.63M
Revenue Q3 2014 · Jun 30, 2014 $82.32M
Revenue Q3 2014 · Jun 30, 2013 $19.76M
Revenue Q3 2014 · Jun 30, 2013 $53.71M